• Home
  •  / Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

OverviewSuggest Edit

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. Its products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. The company also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.

TypePublic
Founded1988
HQTarrytown, USMap
Websiteregeneron.com
Employee Ratings3.9More
Culture scoreC+More
View Jobs (487)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)8,100(+10%)
Job Openings487
Revenue (FY, 2019)$7.9 B(+18%)
Share Price (May 2020)$612.8 (+6%)

Key People/Management at Regeneron Pharmaceuticals

Leonard S. Schleifer

Leonard S. Schleifer

Founder, President & Chief Executive Officer
George D. Yancopoulos

George D. Yancopoulos

Founding Scientist, President & Chief Scientific Officer
Nouhad Husseini

Nouhad Husseini

Senior Vice President, Business Development
Robert E. Landry

Robert E. Landry

Executive Vice President, Finance and Chief Financial Officer
Joseph J. LaRosa

Joseph J. LaRosa

Executive Vice President, General Counsel and Secretary
Beth F. Levine

Beth F. Levine

Senior Vice President, Associate General Counsel, Chief Compliance Officer
Show more

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Washington and in 3 other locations
Tarrytown, US (HQ)
777 Old Saw Mill River Rd
Bernards, US
110 Allen Rd, Basking Ridge
Rensselaer, US
81 Columbia Turnpike
Washington, US
1399 New York Ave NW
Dublin, IE
Harcourt St
Limerick, IE
Raheen Business Park
Show all (7)

Regeneron Pharmaceuticals Financials and Metrics

Regeneron Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Regeneron Pharmaceuticals's revenue was reported to be $7.86 b in FY, 2019 which is a 17.2% increase from the previous period.
USD

Revenue (Q1, 2020)

1.8b

Net income (Q1, 2020)

624.6m

EBIT (Q1, 2020)

700.1m

Market capitalization (29-May-2020)

69.0b

Closing stock price (29-May-2020)

612.8

Cash (31-Mar-2020)

2.2b

EV

67.5b
Regeneron Pharmaceuticals's current market capitalization is $69 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.9b5.9b6.7b7.9b

Revenue growth, %

18%21%14%17%

Cost of goods sold

299.7m397.1m434.1m782.2m

Gross profit

4.6b5.5b6.3b7.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

1.3b1.5b1.5b1.5b1.6b1.7b1.7b1.9b2.0b1.8b

Cost of goods sold

84.2m102.9m104.2m114.9m91.7m110.4m179.2m152.5m226.6m

Gross profit

1.2b1.4b1.4b1.4b1.5b1.6b1.5b1.8b1.8b

Gross profit Margin, %

94%93%93%92%94%93%90%92%89%
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

535.2m812.7m1.5b1.6b

Accounts Receivable

1.6b2.0b2.2b2.7b

Prepaid Expenses

130.5m225.0m243.3m387.1m

Inventories

399.4m726.1m1.2b1.4b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

811.8m744.3m792.1m1.0b917.9m1.1b1.7b1.0b1.4b2.2b

Accounts Receivable

1.7b1.8b2.0b1.9b2.0b2.2b2.3b2.5b2.7b2.1b

Prepaid Expenses

146.1m193.3m143.8m155.5m163.6m284.8m182.2m208.2m226.9m226.6m

Inventories

466.6m554.3m641.6m820.4m928.6m1.0b1.2b1.3b1.3b1.5b
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

895.5m1.2b2.4b2.1b

Depreciation and Amortization

104.7m145.5m148.2m210.3m

Inventories

(149.8m)(314.2m)(387.9m)(335.5m)

Accounts Payable

254.0m(23.2m)210.0m444.5m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

248.9m636.7m1.0b478.0m1.0b1.6b461.1m654.2m1.3b624.6m

Depreciation and Amortization

38.1m73.2m111.0m36.4m70.0m105.4m51.0m103.1m156.0m56.1m

Inventories

(69.7m)(151.5m)(235.6m)(88.8m)(182.1m)(281.6m)(58.6m)(168.2m)(227.2m)(70.8m)

Accounts Payable

187.7m(147.2m)(28.9m)76.7m67.0m179.9m(19.6m)110.3m119.9m(85.2m)
show all
USDY, 2020

EV/EBIT

96.4 x

Financial Leverage

1 x
Show all financial metrics

Regeneron Pharmaceuticals Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patents (US)

6 17 18 21

Product Candidates

16 15 21 22

Products

5 6 7 7

Trademarks

8 9 12 13
Show all operating metrics

Regeneron Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Loop Road Holdings LLC
Old Saw Mill Holdings LLC
OSMR Holdings
OSMR International
OSMR LLC
Regeneron Assurance
Regeneron Atlantic Holdings
Regeneron Belgium BVBA
Regeneron Capital International B.V.
Regeneron Genetics Center LLC
Show more

Regeneron Pharmaceuticals Revenue Breakdown

Embed Graph

Regeneron Pharmaceuticals revenue breakdown by business segment: 33.3% from Sanofi and Bayer Collaboration, 61.5% from Product Sales and 5.3% from Other

Regeneron Pharmaceuticals Online and Social Media Presence

Regeneron Pharmaceuticals's Trends

Embed Graph

Regeneron Pharmaceuticals Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    C+

    72/100

  • Compensation

    B-

    74/100

Learn more on Comparably

Regeneron Pharmaceuticals News and Updates

February 25, 2020

Thinking about trading options or stock in Enphase Energy, Home Depot, Perrigo, Regeneron Pharmaceuticals, or Trade Desk?

NEW YORK, Feb. 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENPH, HD, PRGO, REGN, and TTD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
June 04, 2019

Ophthalmology Market, 2025 - Major Players are Novartis, Bausch & Lomb, F.Hoffman La-Roche, Regeneron Pharmaceuticals, & Allergan

DUBLIN, June 4, 2019 /PRNewswire/ -- The "Global Ophthalmology Market by Segment, by Disease, by Drug Class, by Region - Market Outlook 2025" report has been added to ResearchAndMarkets.com's offering. Ophthalmic drug delivery has been one of the most daunting tasks for clinicians. With...
December 07, 2018

Interleukin 1 (IL1) - Pipeline Review, Competitive Landscape & Overview by key players Opsona Therapeutics, Peptinov SAS, R Pharm, Regeneron Pharmaceuticals

A new independent 97 page research with title 'Interleukin 1 (IL1) - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes important players/vendors such as Apexigen Inc, Link Health Group, Moderna Therapeutics…
November 15, 2018

Retinal Vein Occlusion (RVO) Treatment Market - Global Forecast to 2023, Dominated by Allergan, Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals

DUBLIN, Nov. 15, 2018 /PRNewswire/ -- The "Global Retinal Vein Occlusion Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Global Retinal Vein Occlusion Market to grow at a CAGR of 9.4% during the period 2019-2023. One trend affecting this market...
September 11, 2018

Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals

DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diabetic Macular Edema Treatment Market to grow at a CAGR of 1.45% during the period 2018-2022. Global Diabetic...

Regeneron Pharmaceuticals Blogs

May 13, 2020

Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio

TARRYTOWN, N.Y. , May 13, 2020 /PRNewswire/ -- Regeneron will host investor webcast on Monday, June 1 to discuss oncology program strategy and progress Regeneron Pharmaceuticals, Inc.  (NASDAQ:  REGN ) today announced the company will share updates from its diverse clinical oncology portfolio at
May 11, 2020

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

TARRYTOWN, N.Y. and AURORA, Colo. , May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health records to aid in genomic medicine, drug discovery and personalized medicine approaches
May 05, 2020

Regeneron Reports First Quarter 2020 Financial and Operating Results

TARRYTOWN, N.Y. , May 5, 2020 /PRNewswire/ -- First quarter 2020 revenues increased 33% to $1.83 billion versus first quarter 2019 (4) First quarter EYLEA ® U.S. net sales increased 9% to $1.17 billion versus first quarter 2019 First quarter Dupixent ® global net sales (2) , which are recorded by
May 05, 2020

Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma

TARRYTOWN, N.Y. and PARIS , May 5, 2020 /PRNewswire/ --   Objective responses seen in approximately 29% of patients with locally advanced basal cell carcinoma (BCC) In a preliminary analysis, objective responses seen in 21% of patients with metastatic BCC Approximately 85% of patients who responded
April 27, 2020

Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival

TARRYTOWN, N.Y. and PARIS , April 27, 2020 /PRNewswire/ -- Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan   regulatory submissions in 2020 Regeneron Pharmaceuticals, Inc.  (NASDAQ: REGN ) and Sanofi today announced the primary endpoint of overall
April 27, 2020

Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients

TARRYTOWN, N.Y. and PARIS , April 27, 2020 /PRNewswire/ --  Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced "critical" group with Kevzara higher-dose versus placebo and   discontinuing less advanced "severe" group Phase 3 trial will be
Show more

 Regeneron Pharmaceuticals Frequently Asked Questions

  • When was Regeneron Pharmaceuticals founded?

    Regeneron Pharmaceuticals was founded in 1988.

  • Who are Regeneron Pharmaceuticals key executives?

    Regeneron Pharmaceuticals's key executives are Leonard S. Schleifer, George D. Yancopoulos and Nouhad Husseini.

  • How many employees does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 8,100 employees.

  • What is Regeneron Pharmaceuticals revenue?

    Latest Regeneron Pharmaceuticals annual revenue is $7.9 b.

  • What is Regeneron Pharmaceuticals revenue per employee?

    Latest Regeneron Pharmaceuticals revenue per employee is $970.8 k.

  • Who are Regeneron Pharmaceuticals competitors?

    Competitors of Regeneron Pharmaceuticals include Idorsia, Celgene and Amgen.

  • Where is Regeneron Pharmaceuticals headquarters?

    Regeneron Pharmaceuticals headquarters is located at 777 Old Saw Mill River Rd, Tarrytown.

  • Where are Regeneron Pharmaceuticals offices?

    Regeneron Pharmaceuticals has offices in Tarrytown, Bernards, Rensselaer, Washington and in 3 other locations.

  • How many offices does Regeneron Pharmaceuticals have?

    Regeneron Pharmaceuticals has 7 offices.